GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Net Change in Cash

Knight Therapeutics (TSX:GUD) Net Change in Cash : C$21.3 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Knight Therapeutics's Net Change in Cash for the three months ended in Dec. 2024 was C$6.4 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was C$21.3 Mil.

Knight Therapeutics Net Change in Cash Historical Data

The historical data trend for Knight Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Net Change in Cash Chart

Knight Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.32 -143.63 -14.28 -12.92 21.35

Knight Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.66 4.07 -2.03 12.95 6.35

Knight Therapeutics Net Change in Cash Calculation

Knight Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=36.28+16.963+-33.54+1.642
=21.3

Knight Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=1.469+18.049+-15.354+2.187
=6.4

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$21.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Net Change in Cash
Comparable Companies
TSX:DHT.U NEOE:GLAS.A.U XCNQ:CL NEOE:VRNO TSX:ACB TSX:CPH TSX:WEED TSX:CRON TSX:OGI XCNQ:VREO ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
KHTRF:USA 04K:Germany
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Website
https://www.gud-knight.com
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.
Executives
Sime Armoyan 10% Security Holder
Samira Sakhia Director, Senior Officer
Amal Khouri Senior Officer
Jonathan Ross Goodman Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande Director
Janice Jean Murray Director
Nicolas Sujoy Director
Long Zone Holdings Inc. 10% Security Holder
Arvind Utchanah Senior Officer
Michael Joseph Tremblay Director
James Gale Director
Michael Dehn Director, Senior Officer
Andrew Moor Senior Officer
Patrick Mcclymont Senior Officer
Kevin Drew Nabholz Director

Knight Therapeutics Headlines

No Headlines